- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Diasome Pharmaceuticals, a clinical stage diabetes therapeutics company, today announced that its abstract was selected for presentation at the 69th Scientific Sessions of the American Diabetes Association (ADA), being held June 5-9 at the Morial Convention Center in New Orleans, La. The ADA is the nation's premier voluntary health organization supporting diabetes research, information and advocacy.
Diasome Pharmaceutical's poster presentation will be focusing on the administration of Oral HDV-Insulin in a food-dose timing trial. The following abstract will be presented as a poster from Saturday, June 6 through Monday, June 8 in the Morial Convention Center's Hall D and Hall E:
A Single-Blind, Placebo-Controlled, Food-Dose Timing Trial of Oral HDV-Insulin in Patients with Type 2 Diabetes Mellitus. Blair Geho, MD, PhD, John Lau, Len Rosenberg, PhD, RPh, Sherwyn Schwartz, MD. Diasome Pharmaceuticals, Conshohocken, PA and Diabetes Glandular Research Center, San Antonio, TX.
Diasome's Oral HDV-Insulin is a nanotechnology-based cell targeting system for the improved treatment of diabetes mellitus. This drug delivery system is specifically targeted to hepatocytes, the primary metabolic cells in the liver. Diasome's therapies have been tested in more than 250 subjects through Phase II studies, and have shown the ability to lower blood glucose levels in diabetics.
About Diasome Pharmaceuticals
Diasome Pharmaceuticals, Inc. is a venture-backed biopharmaceutical company focused on novel insulin-based therapies for the improved treatment of diabetes. The Company was formed in late 2004 and has completed multiple Phase II human studies of HDV-Insulin, its proprietary insulin targeting system. Diasome uses a unique, nano-technology based cell targeting system to preferentially deliver insulin to the hepatocytes in the liver. This technology has led to the development of Oral HDV-Insulin, an advanced oral delivery system for insulin. For more information, please visit Diasome’s website at www.diasome.com.
About the American Diabetes Association
The American Diabetes Association (ADA) is the nation’s premier voluntary health organization supporting diabetes research, information and advocacy. Founded in 1940, the Association's mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. The Association's commitment to research is reflected through its scientific meetings; education and provider recognition programs; and its Research Foundation and Nationwide Research Program, which fund breakthrough studies looking into the cure, prevention, and treatment of diabetes and its complications. www.diabetes.org
For more information, please click here
Copyright © BusinessWireIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Dais Analytic Unveils New Version of Aqualyte Membrane Technology: Updates to the Basis of the Company's Industry-Changing Nanotechnology Designed to Strengthen Position in Global Air, Energy, and Water Markets June 26th, 2015
CAP-XX Launches 0.6mm Thinline Supercapacitors for Designing Wearable, Ultra-Portable and Connected IoT Devices: Eliminated Materials and Changed Processes to Reduce Thickness and Costs to Below $1 May 19th, 2015
Chivalrous Knight Does Pro Bono June 27th, 2015
Spain nanotechnology featured at NANO KOREA 2015 June 26th, 2015
Newly-Developed Biosensor in Iran Detects Cocaine Addiction June 23rd, 2015
Researchers first to show that Saharan silver ants can control electromagnetic waves over an extremely broad range of the electromagnetic spectrum—findings may lead to biologically inspired coatings for passive radiative cooling of objects June 19th, 2015
Cellulose from wood can be printed in 3-D June 17th, 2015